Our analysis examining empagliflozin vs dapagliflozin in Stage 3 CKD for kidney outcomes in TriNetX database. Led by @Joyita_4, a formal fellow at @bu_bmc_renal , during her second year of fellowship. @The_BMC @BioMedCentral
pubmed.ncbi.nlm.nih.gov/42277683/
pubmed.ncbi.nlm.nih.gov/42277683/